×
Tips for Using Digital Health Tools
https://www.the-rheumatologist.org/article/tips-for-using-digital-health-tools/
Collins, T.

Dec 18th, 2018 - Approximately 200,000 health apps are available through major app stores. Some offer real benefits, said Brennan Spiegel, MD, MSHS, director of health services research at Cedars-Sinai Health System, Los Angeles, Calif. But most, he told attendees at the 2018 ACR/ARHP Annual Meeting, are “rubbish.”

ACR Leaders Discuss E/M Coding Changes, Step Therapy & More
https://www.the-rheumatologist.org/article/acr-leaders-discuss-e-m-coding-changes-step-therapy-more/
Collins, T.

Dec 18th, 2018 - ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals.

Annual Meeting Speakers Review Studies Ranging from Opioids to Fibroblasts
https://www.the-rheumatologist.org/article/annual-meeting-speakers-review-studies-ranging-from-opioids-to-fibroblasts/
Collins, T.

Dec 18th, 2018 - Findings on opioid efficacy, serum urate in osteoarthritis and arthrocentesis headlined the top research of the year discussed in the first half of a session at the 2018 ACR/ARHP Annual Meeting. The second half covered basic science findings, including summaries of new insights into the gender bias in autoimmune diseases, platelet microparticles in scleroderma and fibroblasts in rheumatoid arth...

New insight gained into natural history of interstitial pneumonia with autoimmune features
https://www.mdedge.com/pulmonary-health-hub/article/191369/lupus-connective-tissue-diseases/new-insight-gained-natural
Bruce Jancin

Dec 17th, 2018 - CHICAGO – Patients who meet the criteria for interstitial pneumonia with autoimmune features are more than 14 times more likely to progress to a systemic autoimmune rheumatic disease than are those with idiopathic interstitial lung disease who don’t meet the criteria, Michail Alevizos, MD, reported at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge News Dr.

Drug-drug interactions in rheumatology patients on PPIs: An underappreciated problem?
https://www.mdedge.com/familymedicine/article/191368/rheumatoid-arthritis/drug-drug-interactions-rheumatology-patients-ppis
MDedge Rheumatology; Bruce Jancin

Dec 17th, 2018 - CHICAGO – Chronic use of proton pump inhibitors is widespread among patients with rheumatoid arthritis or systemic lupus erythematosus, posing a distinct danger of unwelcome drug-drug interactions affecting the rate and extent of absorption of selected oral antirheumatic drugs, Nicholas Jones, PharmD, said at the annual meeting of the American College of Rheumatology. Of particular interest is.

Rheumatologist prescribing rates predict chronic opioid use in RA patients
https://www.mdedge.com/familymedicine/article/191359/rheumatoid-arthritis/rheumatologist-prescribing-rates-predict-chronic
MDedge Rheumatology; Sharon Worcester

Dec 17th, 2018 - CHICAGO – A physician’s baseline opioid prescribing rate strongly predicts future chronic opioid use in rheumatoid arthritis patients, an analysis of data from the Consortium of Rheumatology Researchers of North America (Corrona) Rheumatoid Arthritis Registry suggests. sdominick/iStock/Getty Images The baseline 12-month opioid prescribing rate of 148 physicians in the initial cohort varied wide.

“FAST” indices help to identify fibromyalgia in routine rheumatology care
https://www.mdedge.com/familymedicine/article/191303/pain/fast-indices-help-identify-fibromyalgia-routine-rheumatology-care
MDedge Rheumatology; Sharon Worcester

Dec 17th, 2018 - CHICAGO – Fibromyalgia assessment screening tool (FAST) indices derived from the Multidimensional Health Assessment Questionnaire (MDHAQ) provide a simple and effective method for identifying fibromyalgia in routine care, according to findings from a series of more than 500 patients. Sharon Worcester/MDedge News Dr.

New Guidance for PsA Management
https://www.medpagetoday.com/rheumatology/arthritis/76915

Dec 15th, 2018 - The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released joint treatment guidelines for psoriatic arthritis (PsA). The guidelines provide evidence-based pharmacologic and non-pharmacologic recommendations, and include recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of infl...

Baricitinib study highlights power of placebo effect in RA
https://www.mdedge.com/internalmedicine/article/191253/rheumatoid-arthritis/baricitinib-study-highlights-power-placebo
Bruce Jancin

Dec 14th, 2018 - CHICAGO – After 52 weeks of blinded adalimumab, a switch to 48 weeks of unblinded baricitinib without an adalimumab washout period resulted in an uptick in rheumatoid arthritis control with no flares and no increase in serious adverse events in the phase 3 RA-BEYOND baricitinib long-term extension study, Michael E. Weinblatt, MD, reported at the annual meeting of the American College of Rheumat.

Novel SSc classification scheme aims to improve risk stratification
https://www.mdedge.com/rheumatology/article/191187/lupus-connective-tissue-diseases/novel-ssc-classification-scheme-aims
Sharon Worcester

Dec 14th, 2018 - CHICAGO – A simple new classification scheme that combines autoantibody specificity and extent of skin involvement could improve risk stratification of patients with systemic sclerosis, according to researchers at University College London. “The Le Roy et al.

Combination immunotherapy ups survival in ILD patients with anti-MDA5–positive dermatomyositis
https://www.mdedge.com/pulmonary-health-hub/article/191162/lupus-connective-tissue-diseases/combination-immunotherapy-ups
Sharon Worcester

Dec 13th, 2018 - CHICAGO – Early treatment with combined high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide therapy significantly improves survival vs. step-up therapy in interstitial lung disease patients with anti–melanoma differentiation–associated gene 5 (anti-MDA5)–positive dermatomyositis, according to findings from a prospective, multicenter study.

Anti-TIF1-Ab-Positive Dermatomyositis Linked to Higher Cancer Risk
https://www.medpagetoday.com/rheumatology/generalrheumatology/76902

Dec 13th, 2018 - Action Points Anti-TNF1-Ab positive dermatomyositis (DM) is linked to an elevated risk of cancer, especially ovarian cancer. This risk is present approximately 3 years on either side of DM onset. The link between DM and cancer is present for patients ≥ 39 years of age. CME Author: Zeena Nackerdien Study Authors: Alexander Oldroyd, Jamie C. Sergeant, et al. Target Audience and Goal Statement: Rh...

Obesity ‘significantly’ increases risk for RA in women
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B96e9a441-762f-4bcf-bede-017b3d679250%7D/obesity-significantly-increases-risk-for-ra-in-women

Dec 13th, 2018 - Abdominal obesity heightens the risk for rheumatoid arthritis considerably among women aged 55 years and older regardless of BMI

The 2018 ARHP Merit Awards & ACR Distinguished Fellows
https://www.the-rheumatologist.org/article/the-2018-arhp-merit-awards-acr-distinguished-fellows/
Patton, C.

Dec 12th, 2018 - At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care.

AS linked to increased risk for certain cancer types
https://www.healio.com/rheumatology/spondyloarthropathies/news/online/%7Bfcf5af2c-3605-4c55-8adc-dde4d92d1016%7D/as-linked-to-increased-risk-for-certain-cancer-types

Dec 12th, 2018 - Patients with ankylosing spondylitis had an increased risk for melanoma, hematological malignancies, kidney and thyroid cancer

Top 10 Topics at ACR 2018
https://www.rheumatologynetwork.com/acr/top-10-topics-acr-2018
Robert, L.

Dec 11th, 2018 - Click through the slideshow to find concise summaries of conference highlights.

PASDAS: Targeting Multiple Aspects of PsA
https://www.medpagetoday.com/rheumatology/arthritis/76824

Dec 10th, 2018 - Treatment with secukinumab (Cosentyx) led to sustained remission or low disease activity using a novel, stringent outcome measure in patients with psoriatic arthritis (PsA), a post-hoc analysis of a phase III trial found. On the Psoriatic Arthritis Disease Activity Score (PASDAS), which evaluates multiple aspects of PsA, remission and low disease activity at 16 weeks were achieved by 15.6% and ...

ACR Delegates Move Rheumatology Concerns Forward at AMA
https://www.the-rheumatologist.org/article/acr-delegates-move-rheumatology-concerns-forward-at-ama/

Dec 10th, 2018 - At the AMA’s recent House of Delegates Interim Meeting, the ACR’s delegation was able to incorporate rheumatology concerns into official AMA policy, in addition to leading a major multi-specialty resolution on the CMS-proposed move to consolidate and cut evaluation and management (E/M) services.